ALL PUBLICATIONS

​

   

1.  A.  Perl, B.  Fekete,  P.  Gergely, and  A.G.B.  Kovach (1982) Demonstration of Fc and C3breceptors on rat perikarya. Acta Physiol. Hung. 60, 53‑56. PMID: 6223508

    

2.  A.  Perl, R.  Gonzalez‑Cabello, I.  Lang, and P. Gergely (1982) Depressed natural and lectin‑dependent cell‑mediated cytotoxicity against adherent HEp‑2 cells in patients with systemic lupus erythematosus. Immunol. Comm. 11, 431‑440. PMID: 7169224

    

3.  A.  Perl, E.  Pocsik, R.  Gonzalez‑Cabello, I.  Lang and P.  Gergely (1983) Human lectin‑dependent T‑cell‑mediated cytotoxicity against HEp‑2 cells. Acta Physiol. Hung. 61, 225‑231. PMID: 6606296

    

4.  A.  Perl, R.  Gonzalez‑Cabello, I.  Lang, P. Somos and P. Gergely (1983) Depressed lectin‑dependent cell‑mediated  cytotoxicity  against  adherent  HEp‑2 cells in patients with carcinoma of the uterine cervix. Cancer. Immunol. Immunother. 15, 155‑158. PMID: 6553513

    

5.  A.  Perl, R. Gonzalez‑Cabello, E. Pocsik, I. Lang and P. Gergely (1983) Effect of Fc receptor blocking on human natural and lectin‑dependent cell‑mediated cytotoxicity against adherent HEp‑2 cells. Immunol. Letters, 6, 317‑321.  PMID: 6195101       

 

6.  A.  Perl, R.  Gonzalez‑Cabello and P.  Gergely (1983) Stimulation of lectin‑dependent cell‑mediated cytotoxicity against adherent HEp‑2 cells by carrageenan. Clin. Exp. Immunol. 54, 567‑572. PMID: 6652971; PMCID: PMC1535892

 

7.  E.  Pocsik,  R.  Gonzalez‑Cabello,  K.  Benedek, A.  Perl,  I.  Lang  and  P.  Gergely  (1983) Characterization of the effector cells in Con A‑induced cytotoxicity against HEp‑2 tumour targets. Acta Med. Hung. 40, 41‑46. PMID: 6607455

 

8.  A. Perl, R. Gonzalez‑Cabello, I. Lang and P. Gergely (1984) Effector activity of OKT4+ and OKT8+ T‑cell subsets in lectin‑dependent cell‑mediated cytotoxicity against adherent HEp‑2 cells. Cell. Immunol. 84, 185‑193. PMID: 6230158

 

9.  P.  Gergely,  K.  Nekam,  I.  Lang,  L.  Kalmar,  R.  Gonzalez‑Cabello and A. Perl (1984) Ketoconazole   in   vitro   inhibits   mitogen‑induced   blastogenesis, antibody‑dependent cellular cytotoxicity,   natural    killer    activity    and    random    migration    of    human    leukocytes. Immunopharmacology, 7, 167‑170. PMID: 6088429

 

10.  A.  Perl, R.  Gonzalez‑Cabello and P. Gergely (1984) Depressed effector activity of OKT4+ and   OKT8+  T‑cell  subsets  in  lectin‑dependent  cell‑mediated  cytotoxicity  to  HEp‑2  cells  in patients with systemic lupus erythematosus. J. Clin. Lab. Immunol. 15, 95‑100. PMID: 6240539

 

11. Lang I, Feuer L, Nekam K, Perl A, Szigeti A, Gergely P, Feher J. (1984) Effect of Litoralon therapy on the lymphocytotoxicity in patients with malignant tumors (In Hungarian). Orv. Hetil. 125:2193-2196. PMID: 6472845

 

12.  J.  Feher,  A.  Cornides,  A.  Vereckei,  I.  Lang,  K. Nekam, A. Perl and P. Gergely (1984) Immunomodulatory effect of new radical scavengers. Drugs Expt. Clin. Res. X(8‑9) 549‑562.

 

13.   K.   Nekam,  I.  Lang,  L.  Kalmar, A. Perl  and  P.  Gergely  (1984)  Isoprinosine:  recent experimental  and  therapeutic  results  with an antiviral immune modifier. Tissue Cult. Res, 173‑178.

 

14.  A. Perl, R. Gonzalez‑Cabello, K. Benedek, K. Nekam, I. Lang and P. Gergely  (1985) Effect of  histamin‑receptor  blocking  on  human  natural  and lectin‑dependent cell‑mediated cytotoxicity against adherent HEp‑2 cells. Thymus, 7, 111‑118. PMID: 4012822

 

15. A. Perl, R. Gonzalez‑Cabello, I. Lang and P. Gergely (1985) Depressed lectin‑dependent cell‑ mediated  cytotoxicity against  HEp‑2  cells in patients with different metastatic solid tumors. Acta Physiol. Hung. 65, 149‑153. PMID: 3872553

 

16.  A.  Perl, R.  Gonzalez‑Cabello,  L.  Falucskai, P.  Gergely, and J. Feher (1985) Contrasting effects of RNA and protein synthesis blocking on natural and lectin‑dependent cell‑mediated cytotoxicity against adherent HEp‑2 cells. Experientia, 41, 1344‑1346. PMID: 2412880

 

 

17.  A.  Perl,  R.  Gonzalez‑Cabello,  K.  Nekam,  P.  Gergely  and J Feher (1985) Stimulation by thymopoietin  oligopeptides of lectin‑dependent cell‑mediated cytotoxicity in patients with systemic lupus erythematosus. J. Clin. Lab. Immunol. 18, 119‑122. PMID: 3910838

 

18.  A.  Perl,  I.  Lang,  R. Gonzalez‑Cabello, J. Filep, K. Nekam, P. Gergely and J Feher (1986) Indomethacin   abrogates   the  suppression  by  cyclosporin  A  of  lectin‑dependent  cell‑mediated cytotoxicity to HEp‑2 cells. Immunopharmacology, 11, 39‑45. PMID: 3957649

 

19.  A.  Perl,  R.  Gonzalez‑Cabello,  T.  Laskay, M. Benczúr, I. Lang, K. Onody, K. Nekam, P. Gergely and J Feher (1986) Lectin‑dependent cell‑mediated cytotoxicity and blastogenesis by LGL‑enriched and depleted lymphocytes. Clin. Exp. Immunol. 63, 171‑178. PMID: 3955881; PMCID: PMC1577327

 

20.  A.  Perl,  G. Repassy, R. Gonzalez‑Cabello, I. Lang and P. Gergely (1986) Depressed lectin‑dependent  and  augmented  antibody‑dependent  cell‑mediated  cytotoxicity in patients with stage I cancer of the larynx. Natural Immunity and Cell Growth Regulation, 5, 100‑106. PMID: 3487714

 

21.  A.  Perl,  R.  Gonzalez‑Cabello,  K.  Onody, I. Bodo and P. Gergely (1986) Independence of depressed  lectin‑dependent  cell‑mediated  cytotoxicity  from  interleukin‑2  production  in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 65, 286‑292. PMID: 3491706

 

22.  A. Perl, A. Szigeti, P. Gergely, J. Feher, E. Magyarosi and M. Sellyei (1986) Abrogation by chemotherapy  of  T‑cell  antigen  expression  in  B‑cell chronic lymphocytic leukemia. N. Engl. J. Med. 314, 186‑187. PMID: 2417119

 

23.  A.  Perl, R.J.  Looney, D.H.  Ryan and  G.N. Abraham (1986) The low affinity 40 kD Fc‑gamma receptor and the transferrin receptor can be alternative or simultaneous target structures on cells sensitive for natural killing. J. Immunol. 136, 4714‑4720.

    

24.  T. Bakacs, K. Totpal, G. Ringwald, A. Perl and P. Gergely (1986) Quantitative determination of  anti‑A‑dependent  cytotoxicity  of  human  peripheral blood monocytes. J. Clin. Lab. Immunol. 19, 143‑147.

 

25. R. Gonzalez‑Cabello,  A.  Perl,  L.  Kalmar and P. Gergely (1987) Short‑term stimulation of lymphocyte proliferation by indomethacin in vitro and in vivo. Acta Physiol. Hung. 70, 25‑30.

 

26.  J.  Feher,  I.  Lang,  Zs.  Pollak,  K.  Nekam,  R.  Gonzalez‑Cabello, A. Perl and P. Gergely (1987)  Immunomodulatory and membrane protective effect of dihydroquinoline type antioxidants. In: Progress in Radio‑Oncology, Ed.: Karcher, K.H., ICRO, Vienna, pp. 218.

 

27.  K. Nekam, A. Perl, P. Gergely, R. Gonzalez‑Cabello and J. Feher (1987) Effect of dialyzable lymphocyte  extracts  on  lectin‑dependent cell mediated cytotoxicity in vitro. In Proceedings of the Fifth International Symposium on  Transfer  Factor.  Mayer  V. and Borvak J. (Eds.) Bratislava, Czechoslovakia.

 

28  I.  Lang,  K.  Nekam,  Gy.  Deak,  G.  Muzes,  R.  Gonzalez‑Cabello,  J.  Kadar, A. Perl, P. Gergely  and  J.  Feher  (1987)  Effect  of  (+)cyanidanol‑3  on  cellular  immune reactions and on superoxide dismutase activity in vitro. Free Rad. Res. Comm. 4, 51‑60.

 

29.  A.  Cornides,  J.  Feher,  A. Perl, P. Gergely and A. Gogl (1987) Metronidazol induced liver injury. Hepatology, 18, 11‑13.

 

30.  A.  Perl,  N. Wang, J.M. Williams, M.J. Hunt, S.I. Rosenfeld, J.J. Condemi, C.H. Packman and  G.N.  Abraham  (1987)  Aberrant immunoglobulin and c‑myc gene rearrangements in patients with non‑malignant monoclonal cryoglobulinemia. J. Immunol. 139, 3512‑3520.

 

31.  A.  Perl,  P.D.  Gorevic,  D.H.  Ryan,  J.J.  Condemi,  R.J. Ruszkowski and G.N. Abraham (1989)  Clonal  B‑cell  expansions  in  patients  with  essential mixed cryoglobulinemia. Clin. Exp. Immunol. 76, 54‑60.

 

32.  A. Perl, J.P. DiVincenzo, P. Gergely, J.J. Condemi and G.N. Abraham (1989) Detection and mapping   of   polymorphic  KpnI  alleles  in  the  human  T‑cell  receptor  constant  beta‑2  locus. Immunology, 67, 135‑138.

 

33.  A.  Perl,  J.D.  Rosenblatt,  I.S.Y.  Chen, J.P. DiVincenzo, R. Bever , B.J. Poiesz, and G.N.

Abraham  (1989)  Detection  and  cloning  of  new HTLV‑related sequences in man. Nucleic Acids Res., 17, 6841‑6854.

 

34.  A.  Perl,  J.P.  Divincenzo,  D.H. Ryan, P. Gergely, A. Szigeti, J. Feher and G.N. Abraham (1990)  Rearrangement  of the T‑cell receptor alpha, beta and gamma chain genes in B‑cell chronic lymphocytic leukemia. Leukemia Res. 14, 131‑137.

 

35.  G.N.  Abraham,  A.  Perl,  P.D.  Gorevic,  J.M.  Williams,  G. Jones, and R.A. Kyle (1990) Molecular  genetic  analysis  of  human  monoclonal  gammopathies.  In: Biomedical  Advances  in Aging (Ed. A.L. Goldstein). Plenum Press, New York, pp. 355‑362.

 

36. Perl A, Feher J. Polymerase chain reaction in clinical diagnosis (In Hungarian). (1990) Orv. Hetil. 131:671-675.

 

37.  Perl, A.  (1990)  Role of a prostaglandin E1 analogue in prevention of acute graft rejection by cyclosporin A. N. Engl. J. Med., 323, 831‑832.

 

38.  A.  Perl,   K.  Nagy,  T.  Pazmany,  C. Isaacs, K. Baraczka, T. Szabo, & J. Feher (1990) No

evidence  for  HTLV‑I  or HTLV‑II infection in patients with multiple sclerosis. Arch. Neurol. 47, 1061‑1063.

 

39.  Perl,  A.,  Gorevic,  P.D.,  Condemi,  J.J.,  Papsidero,  L., Poiesz, B.J. and Abraham, G.N.

(1991)  Antibodies  to retroviral proteins and reverse transcriptase activity in patients with essential cryoglobulinemia. Arthritis. Rheum. 34, 1313‑1318.

 

40.  Perl, A., Isaacs, C.M.,  Eddy, R.L., Byers, M.G.,and Shows, T.B. (1991) The human T‑cell

leukemia  virus‑related  endogenous  sequence  (HRES‑1)  is  located  on  chromosome  1  at  q42. Genomics, 11, 1172‑1173.

 

41.  Banki,  K.,  J.S. Maceda, E. Hurley, E. Ablonczy, D. Mattson, L. Szegedy, C. Hung and A.

Perl  (1992)  HRES‑1, a human endogenous retroviral sequence encodes a 28 kd protein: a possible autoantigen for HTLV gag‑reactive autoantibodies. Proc. Natl. Acad. Sci. USA, 89, 1939‑1943.

 

42.  Krieg, A.M., Gourley, M.F. and Perl, A. (1992) Endogenous retroviruses: Potential etiologic

agents in autoimmunity. FASEB J. 6:2537‑2544.

 

43.  Srivastava, B.I.S., Banki, K. & Perl, A. (1992) Detection of human T‑cell lymphotropic virus type  I  or  a  related  retrovirus  in  patients  with mycosis fungoides, Sezary syndrome and Kaposi sarcoma. Cancer Res. 52, 4391‑4395.

 

44.   Krieg,  A.M.,  Gourley,  M.F.,  Klinman,  D.M.,  Perl,  A.,  and  Steinberg,  A.D.  (1992)

Heterogenous  expression  and  induction  of  human endogenous retroviral sequences in peripheral blood   mononuclear   cells   from  patients  with   polymyositis  and  controls.  AIDS Res. Hum. Retrovirus. 12, 1991‑1998.

 

45.  Perl, A. and Banki, K. (1993) Human endogenous retroviral elements and autoimmunity: data and concepts. Trends Microbiol. 1:153‑156.

 

46.  Agarwal, R.K. and Perl, A. (1993) PCR amplification  of highly GC‑rich DNA template after denaturation by NaOH. Nucleic Acids Res. 21, 5283‑5284.

 

47.  Banki,  K.,  Halladay, D. and Perl, A. (1994) Cloning and Expression of the Human Gene for Transaldolase:  a  Novel  Highly  Repetitive  Element  Constitutes  an  Integral  Part of the Coding Sequence. J. Biol. Chem. 269:2847‑2851.

 

48.   Banki,   K.,   É.   Ablonczy,  M.  Nakamura,  and  Perl,  A.  (1994)  Effect  of  the  p40/tax

transactivator  of  human T‑cell lymphotropic virus type I (HTLV‑I) on expression of autoantigens. AIDS Res. Hum. Retrovirus 10:303-308.

 

49.  Magistrelli, C.,  Halladay, D., Agarwal, R., Ferrante, P., Perl, A. (1994) Mapping and cloning of polymorphic genotypes of the HRES-1 LTR. FASEB J. 8:A4395, manuscript in preparation.

 

50. Banki, K., E. Colombo, F. Sia, D. Halladay, D. H. Mattson, A.H. Tatum, P. T. Massa,  P. E. Phillips, Perl, A. (1994) Oligodendrocyte‑specific expression and autoantigenicity of transaldolase in multiple sclerosis. J. Exp. Med. 180:1649-1663.

 

51. Perl, A., Colombo, E., Dai, H., Agarwal, R.K., Mark, K., Banki, K., Poiesz, B.J., Phillips, P.E., Hoch, S.O., Reveille, J.D. and Arnett, F.C. (1995). Antibody reactivity to the HRES-1 endogenous retroviral element identifies a subset of patients with systemic lupus erythematosus and overlap syndromes: Correlation with antinuclear antibodies and HLA class II alleles. Arthritis Rheum. 38: 1660-1671.

 

52. Banki, K. and Perl, A. (1996) Inhibition of the catalytic activity of human transaldolase by antibodies and site-directed mutagenesis. FEBS Lett. 378: 161-165.

 

53. Banki, K., Hutter, E., Colombo, E., Gonchoroff, N.J. and Perl, A. (1996) Glutathione levels and sensitivity to apoptosis are regulated by changes in transaldolase expression. J. Biol. Chem. 271: 32994-33001.

 

54. Colombo, E., Banki, K., Tatum, A.H., Daucher, J., Ferrante, P., Murray, R.S., Phillips, P.E. and Perl, A. (1997) Comparative analysis of antibody and cell-mediated autoimmunity to transaldolase and myelin basic protein in patients with multiple sclerosis. J. Clin. Invest. 99:1238-1250.

 

55. Banki, K., Eddy, R.L., Shows, T.B., Halladay, D.L., Bullrich, F., Croce, C.M., Jurecic, V., Baldini, A. and Perl, A. (1997) The human transaldolase gene is located on chromosome 11 at p15.4-p15.5. Genomics, 45: 233-238.

 

56. Banki, K., Hutter, E., Gonchoroff, N.J. and Perl, A. (1998) Molecular ordering in HIV-induced apoptosis: oxidative stress, activation of caspases and cell survival are regulated by transaldolase. J. Biol. Chem. 273:11944-11953.

 

57. Banki, K., Hutter, E., Gonchoroff, N.J. and Perl, A. (1999) Elevation of mitochondrial transmembrane potential and ROI levels are early events and independent from activation of caspases in Fas signaling. J. Immunol. 162:1466-1479. PMID: 9973403; PMCID: PMC4020419

 

58. Magistrelli, C., Samoilova, E., Agarwal, R.K., Banki, K., Ferrante, P., Vladutiu, A., Phillips, P.E. and Perl, A. (1999) Polymorphic genotypes of the HRES‑1 human endogenous retrovirus locus are associated with systemic lupus erythematosus and autoreactivity. Immunogenetics, 49:829-834.

 

59. Esposito, M., Venkatesh, V., Otvos,  L., Weng, Z., Vajda, S., Banki, K. and Perl, A. (1999) Human transaldolase and cross-reactive viral epitopes identified by autoantibodies of multiple sclerosis patients. J. Immunol. 163:4027-4032.

 

60. Perl, A. (1999) Mechanisms of viral pathogenesis in rheumatic diseases. Leader. Ann. Rheum. Dis. 58:454-461.

 

61. Perl, A., Colombo, E., Samoilova, E., Butler, M.C. and Banki. K. (2000) Human transaldolase-associated repetitive elements are transcribed by RNA polymerase III. J. Biol. Chem. 275:7261-7272.

 

62.  Puskas, F., Gergely, P. Jr., Banki, K. And Perl. A (2000) Stimulation of the pentose phosphate pathway and glutathione levels by dehydroascorbate, the oxidized form of vitamin C. FASEB J. 14: 1352-1361.

 

63. Thorell, S, Gergely, P.Jr., Banki, K. , Perl, A., Schneider, G. (2000) The three-dimensional structure of human transaldolase. FEBS Lett. 475:205-208.

 

64. Perl,  A., Banki, K. (2000) Genetic and metabolic control of the mitochondrial transmembrane potential and reactive oxygen intermediate production in HIV disease. Invited review. Antiox. Redox Signal., 2:551-573.

 

65. Perl, A. (2001) Editorial. Endogenous Retroviruses in Pathogenesis of Autoimmunity. J. Rheumatol. 28:461-464.

 

66. Lachaise, F., Martin, G., Drougard, C., Perl, A, Vuillaume, M., Wegnez, M., Sarasin, A., Daya-Grosjean, L. (2001) Relationship between post-translational modification of transaldolase and catalase deficiency in UV-sensitive repair-deficient Xeroderma pigmentosum fibroblasts and SV40-transformed human cells. Free Rad. Biol. Med. 30:1365-1373.

 

67. Perl, A. (2001) Abnormal Apoptosis in Systemic Lupus. Lupus News, 21:16-17.

 

68. Gergely, P. Jr., Grossman, C., Niland, B., Puskas, F., Neupane, H., Allam, F., Banki, K.,  Phillips, P.E. and Perl, A. (2002) Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 46:175-190. PMID: 11817589; PMCID: PMC4020417

 

69. Puskas, F., Gergely, P., Niland, B., Banki, K. and Perl, A. (2002) Differential regulation of hydrogen peroxide and Fas-dependent apoptosis pathways by dehydroascorbate, the oxidized form of vitamin C. Antiox. Redox Signal. 4:357-369.

 

70. Perl, A,  Gergely, P., Puskas, F. and Banki, K. (2002) Metabolic switches of T cell activation and apoptosis. Antiox. Redox Signal. 4:427-443.

 

71. Kammer, G.M., Perl, A., Richardson, B.C., Tsokos, G.C. (2002) Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis Rheum. 46:1139-1154.

 

72. Gergely, P. Jr., Niland, B., Gonchoroff, N., Pullmann, R. Jr., Phillips, P.E. and Perl, A.(2002) Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus. J. Immunol. 169:1092-1101.

 

73. Nagy, Gy, Koncz, A. and Perl A (2003) T cell activation-induced mitochondrial hyperpolarization is mediated by Ca2+- and redox-dependent production of nitric oxide. J. Immunol. 171:5188-5197.

 

74.  Mukhopadhyay, S., Mousa, S., George, B.R. and Perl, A. (2004) Palpable purpura, polyarthritis, and abdominal pain. Med. J. Aust. 180:121-122.

 

75. Perl, A., Gergely, P. Jr., Nagy, G., Koncz, A., and Banki, K. (2004). Mitochondrial hyperpolarization: a checkpoint of T-cell life, death, and autoimmunity. Trends Immunol. 25:360-367.

 

76. Grossman, C. E., Qian, Y., Banki, K., Perl, A. (2004) ZNF143 mediates basal and tissue-specific expression of human transaldolase. J. Biol. Chem. 279: 12190-12205.

 

77. Perl,A.; Gergely,P.,Jr.; Banki,K. (2004) Mitochondrial dysfunction in T cells of patients with systemic lupus erythematosus. Int. Rev. Immunol. 23:293-313.

 

78. Grossman, C. E., Niland, B., Stancato, C, Verhoeven, N.M., van der Knaap, M.S., Jakobs, C., Brown, L.M.,  Vajda, S., Banki, K.  and  Perl, A. (2004) Deletion of serine 171 causes inactivation, proteasome-mediated degradation and complete deficiency of human transaldolase. Biochem. J. 382:725-231.

 

79. Nagy, Gy, Barcza. M., Gonchoroff, N., Phillips, P.E. and Perl, A. (2004) Nitric oxide-dependent mitochondrial biogenesis generates Ca2+ signaling profile of lupus T cells. J. Immunol. 173:3676-3683. PMID: 15356113; PMCID: PMC4034140

 

80. Nagy, Gy, Koncz, A, Phillips, P.E. and Perl, A. (2005) Mitochondrial signal transduction abnormalities in systemic lupus erythematosus. Curr. Immunol. Rev. 1: 61-67.

 

81. Gergely. P. Jr,  Pullmann, R., Stancato, C., Otvos, L. Jr, Koncz, A., Blazsek, A., Poor, Gy,  Brown, K.E., Phillips, P.E. and Andras Perl. (2005) Increased prevalence of transfusion-transmitted virus and cross-reactivity with immunodominant epitopes of the HRES-1/p28 endogenous retroviral autoantigen in patients with systemic lupus erythematosus. Clin. Immunol. 116: 124-134.

 

82. Nagy, Gy, Koncz, A, and Perl, A. (2005) T- and B-cell abnormalities in systemic lupus erythematosus. Crit. Rev. Immunol. 25: 123-140.

 

83. Nagy, Gy, Koncz, A, and Perl, A. (2005) Signal transduction abnormalities in systemic lupus erythematosus (In Hungarian). Orv. Hetil. 146:1625-1630.

 

84. Niland, B., Banki, K., Biddison, W.E. and Perl, A. (2005) CD8+ T cell-mediated HLA-A*0201-restricted cytotoxicity to transaldolase peptide 168-176 in patients with multiple sclerosis. J. Immunol. 175: 8365-8378.

 

85. Quintero M, Mirza N, Chang H, Perl A. (2006) Antiphospholipid antibody syndrome associated with primary angiitis of the central nervous system: report of two biopsy-proven cases. Ann. Rheum. Dis. 65 :408‑9

 

86. Nagy G. and Perl, A. (2006) The role of nitric oxide in abnormal T cell signal transduction in systemic lupus erythematosus. Clin. Immunol. 118: 145-151.

 

87. Vas, Gy., Conkrite, K., Amidon, W., Qian, Y., Banki, K., and Perl, A. (2006) Study of transaldolase deficiency in urine samples by LC-MS/MS. J. Mass. Spec. 41: 463-469.

 

88. Fernandez, D., Bonilla, E., Mirza, N, Niland, B. and Perl, A. (2006) Rapamycin reduces disease activity and normalizes T-cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 54: 2983-2988. PMID:16947529; PMCID: PMC4034146

 

89. Perl, A., Qian, Y, Chohan, K.R., Shirley, C.R., Amidon, W., Banerjee, S., Middleton, F.A., Conkrite, K.L., Barcza, M., Gonchoroff, N., Suarez, S.S., and Banki, K. (2006) Transaldolase is essential for maintenance of the mitochondrial transmembrane potential and fertility of spermatozoa. Proc. Natl. Acad. Sci. USA, 103: 14813-14818. PMID:17003133; PMCID: PMC1595434

 

90. Nagy, G., Ward, J., Mosser, D.D., Koncz, A., Gergely, P. Jr., Stancato, S., Qian, Y, Fernandez, D., Niland, B., Grossman, C.E., Telarico, T, Banki, K, Perl, A. (2006) Regulation of CD4 expression via recycling by HRES‑1/RAB4 controls susceptibility to HIV infection. J. Biol. Chem. 281: 34574-34591. PMID:16935861

 

 

91. Fernandez, D., Bonilla, E., Phillips, P.E. and Perl, A. (2006)  Signaling abnormalities in systemic lupus erythematosus as potential drug targets. Endocrin, Metabolic & Immune Disorders - Drug Targets. 6: 305-311.

 

92. Gergely, P., Perl, A. and Poor, Gy. (2006) Possible pathogenic nature of the recently discovered TT virus.  Does it play a role in autoimmune rheumatic diseases? Autoimmun. Rev. 6:5-9.

 

93. LaRocca, D., Lehmann, D.F., Perl, A., Ozawa, T., Holohan, P. D. (2006) The combination of nuclear and mitochondrial mutations as a risk factor for idiosyncratic toxicity. Brit. J. Clin. Pharm. 63:249-251.
 

94. Silberstein, M., Landon, M.R., Wang, Y.E., Perl, A. and Vajda, S. (2006) Computational methods for functional site identification suggest a substrate access channel in transaldolase. Genome Inform. 17: 13-22.
 

95. Koros, A., Hanczko, R., Jambor, Qian, Y., Perl, A. and Molnar-Perl, I. (2007) Analysis of amino acids and biogenic amines in biological tissues as their o-phthalaldehyde/ethanethiol/fluorenylmethyl chloroformate derivatives by high-performance liquid chromatography: A deproteinization study. J. Chromatogr. A 1149: 46-55.

 

96. Nagy, G., Koncz, A., Fernandez, D. and Perl A. (2007). Nitric oxide, mitochondrial hyperpolarization, and T-cell activation. Free Radic. Biol. Med. 42: 1625-1631.

 

97. Perl, A. (2007) The pathogenesis of transaldolase deficiency. IUBMB Life 59: 365-373.

 

98. Bonilla, E., Francis, L., Allam, F., Ogrinc, M., Neupane, H., Phillips, P.E., and Perl, A. (2007) Immunofluorescence microscopy is superior to fluorescent beads for detection of antinuclear antibody reactivity in systemic lupus erythematosus patients. Clin. Immunol. 124:18-21.

 

99. Hanczko, R., Jambor, A., Perl, A., and I Molnar-Perl (2007) Advances in the o-phthalaldehyde derivatizations: Comeback to the o-phthalaldehyde–ethanethiol reagent. J. Chromatogr. A 1163: 25-42.

 

100. Bonilla, E., Lee, Y.Y., Phillips, P.E., and Perl, A. (2007) Hypoglycaemia after initiation of etanercept treatment in a patient with type 2 diabetes mellitus. Ann. Rheum. Dis. 66:1688.

 

101. Pullmann, R. Jr., Bonilla, E., Phillips, P.E., Middleton, F.A. and Perl, A. (2008) Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of systemic lupus erythematosus. Arthritis Rheum. 58: 532-540. PMID: 18240231

 

102. Francis L, Bonilla E, Soforo E, Neupane H, Nakhla H, Fuller C, and Perl A. (2008) Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin. Clin. Rheumatol. 27:129-31.

 

103. Perl, A., Nagy, G., Koncz, A., Gergely, P., Fernandez, D., Doherty, E., Telarico, T., Bonilla, E. and Phillips, P.E. (2008) Molecular mimicry and immunomodulation by the HRES-1 endogenous retrovirus in SLE. Autoimmunity, 41:287-297. PMID: 18432409PMID:18432409

DOI: 10.1080/08916930802024764

 

104. Qian, Y., Banerjee, S., Grossman, C.E., Amidon, A., Nagy, Gy., Barcza, M., Niland, B.,  Karp, D.R., Banki, K., and Perl, A. (2008) Transaldolase deficiency influences the pentose phosphate pathway, mitochondrial homeostasis, and apoptosis signal processing. Biochem. J. 415:123-134.

 

105. Vyshkina, T., Sylvester, A., Sadiq, S., Bonilla, E., Canter, J., Perl, A. and Kalman, B.(2008) Association of Common Mitochondrial DNA Variants with Multiple Sclerosis and Systemic Lupus Erythematosus. Clin. Immunol. 129:31-35.

 

106. Vyshkina, T., Sylvester, A., Sadiq, S., Bonilla, E., Perl, A. and Kalman, B.(2008) CCL genes in multiple sclerosis and systemic lupus erythematosus. J. Neuroimmunol. 200:145-152.

 

107. Perl, A. (2009) Overview of Signal Processing by the Immune System in SLE. Autoimmun. Rev. 8:177-178.

 

108. Fernandez D.R. and  Perl, A. (2009) Metabolic control of T-cell activation and death in SLE. Autoimmun. Rev. 8:184-189.

 

109. Fernandez, D.R. Telarico, T., Bonilla, E., Li, Q., Banerjee, S., Middleton, F.A., Phillips, P.E.,  Crow, M.K., Oess, S., Muller-Esterl, W., and Perl, A. (2009) Activation of mTOR controls the loss of TCRζ in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J. Immunol. 182: 2063-2073. PMID:19201859; PMCID: PMC2676112

 

110. Hanczko, R., Fernandez, D.R., Doherty, E.,  Qian, Y., Vas, G., Niland, B., Telarico, T., Garba, A., Banerjee, S., Middleton, F.A., Barrett, D., Barcza, M., Banki, K., Landas, S.K. and Perl, A. (2009) Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J. Clin. Invest. 119:1546-1557. PMID: 19436114; PMCID: PMC2689120

 

111. Francis, L. and Perl. A. (2009) Pharmacotherapy of SLE. Expert Opin. Pharmacother. 10: 1481-1494.

 

112. Perl, A., Fernandez, D., Telarico, T., Francis, L. and Phillips, P.E. (2009) T- and B-cell signaling biomarkers and treatment targets in lupus. Curr. Opin. Rheumatol. 21: 454-464.

 

113. Perl, A. (2009) Editorial: Emerging New Pathways of Pathogenesis and Targets for Treatment in Systemic Lupus Erythematosus and Sjogren's Syndrome. Curr. Opin. Rheumatol. 21: 443-447.

 

114. Bedoya, F.,  Medveczky, M.M.,  Lund, T.C., Perl, A., Horvath, J., Jett, S.D. and Medveczky, P.G. (2009) Identification of Mitochondrial Genome Concatamers in AIDS-associated lymphomas and lymphoid cell lines. Leuk. Res. 33:1499-1504.

 

115. Tily, HI and Perl, A. (2009) Lymphedema: a paradoxical effect of tumor necrosis factor inhibitors – case report and review of literature. BMJ Case Reports [doi:10.1136/bcr.07.2008.0520]

 

116. Blank, M., Shoenfeld, Y. and Perl, A. (2009) Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus. Lupus, 18: 1136-1143.

 

117. Soforo, E., Baumgartner, M., Francis, L., Allam, F., Phillips, P.E., and Perl, A. (2010) Induction of systemic lupus erythematosus with TNF blockers. J. Rheumatol. 37:204-205.

 

118. Francis, L. and Perl. A. (2010) Infection in systemic lupus erythematosus: friend or foe? Int. J. Clin. Rheumatol. 5:59-74.

 

119. Perl, A. (2010) Editorial: Pathogenic Mechanisms in Systemic Lupus Erythematosus. Autoimmunity, 43:1-6.

 

120. Perl, A. (2010) Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance and selecting targets for treatment. Autoimmunity 43: 32-47.

 

121. Tily, H., Banki, K., Hoffman, G.S. and Perl. A. (2010) Detection of lupus anti-coagulant and successful anti-coagulation in familial Sneddon syndrome. Ann. Rheum. Dis. 69: 775-776.

 

122. Niland, B, Miklossy, G,  Banki, K, Biddison, W.E.,  Casciola-Rosen, L., Rosen, A.,  Martinvalet, D., Lieberman, J., and Perl, A. (2010) Cleavage of transaldolase by granzyme B causes the loss of enzymatic activity with retention of antigenicity for multiple sclerosis patients. J. Immunol., 184:4025-32.

 

123. Perl, A., Fernandez, D., Telarico, T, and Phillips P.E. (2010). Endogenous retroviral pathogenesis in lupus. Curr. Opin. Rheumatol. 22:483-492.

 

124. Nagy, G., Koncz, A., Telarico, T., Fernandez, D., Ersek, B., Buzas, E., and Perl, A. (2010) Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Arth. Res. Ther. 12:N. (http://arthritis-research.com/content/12/3/N)

 

125. Engelke, Udo F.H., Fokje S.M. Zijlstra, Fanny Mochel, Vassili Valayannopoulos, Daniel Rabier, Leo A.J. Kluijtmans, Andras Perl, Nanda Verhoeven-Duif, Pascale de Lonlay-Debeney, Mirjam M. Wamelink, Cornelis Jakobs, Éva Morava, Ron A. Wevers. (2010) Erythronic Acid as a Novel Biomarker in Transaldolase Deficiency. Biochim. Biophys. Acta  - Molecular Basis of Disease. 1802 (11):1028-1035.

 

126. Fernandez, D. and Perl, A. (2010) mTOR Signaling: A Central Pathway to Pathogenesis in Systemic Lupus Erythematosus? Discov. Med.  9:173-178.

 

127. Hernández-Negrete, I, Sala-Newby, G.B., Perl, A, Kunkel, G.R., Newby, A.C. and Bond, M.(2011) Adhesion-dependent SKP2 transcription requires selenocysteine tRNA gene transcription activating factor (STAF). Biochem. J. 436:133-143.

 

128. Perl, A. (2011) Deleterious effects of TNF blockade in SLE. J. Rheumatol. 38:1217.

 

129. Perl, A., Hanczko, R., Telarico, T., Oaks, Z. and Landas S. (2011). Control of oxidative stress, inflammation, and carcinogenesis through the pentose phosphate pathway by transaldolase. Trends Mol. Med. 17: 395-403. PMID: 21376665

 

130. Sreih, A., Ezzeddine, R., Leng, L., Lachance, A., Yu, G., Mizue, Y., Pons-Estel, B., Abelson, A-K.,  Gunnarsson, I., Svenungsson, E., Cavett, J., Glenn, S., Zhang, L., Montgomery, R., Perl, A., Salmon, J., Alarcon-Riquelme, M., Harley, J.B., Bucala, R. (2011) Dual Effect of Macrophage Migration Inhibitory Factor Gene on the Development and the Severity of Human Systemic Lupus Erythematosus. Arthritis Rheum. 63: 3942-3951.

 

131. Talaber, G. and Perl, A. (2011) SLE: a Metabolic Disease of T Cells? OMICS Rheumatology 1:e103. http://dx.doi.org/10.4172/2161-1149.1000e103

 

132. Talaber G, Perl A (2012) The molecular pathogenesis of SLE. Immunolologia Szemle (Immunological Quarterly, Hungarian with English abstract) 1:4-11

 

133. Perl, A. (2012) Editorial. Oxidative stress and endosome recycling are complementary mechanisms reorganizing the T-cell receptor signaling complex in SLE. Clin. Immunol. 142: 219-222.

​

134. Perry, D.J., Yin, Y, Telarico, T., Baker, H.V., Dozmorov, I, Perl, A. and Morel, L. (2012) Murine Lupus Susceptibility Locus Sle1c2 Mediates CD4+ T cell Activation and Maps to Estrogen-Related Receptor Gamma Esrrg. J. Immunol. 189: 793-803. PMID: 22711888 22711888; PMCID: PMC3392454

135. Caza, T.N., Talaber, G. and Perl, A. (2012) Metabolic regulation of organelle homeostasis in lupus T cells. Clin. Immunol. 144: 200-213. PMID: 22836085

 

136. Meszaros, Z., Perl, A, Faraone, S. (2012) Psychiatric symptoms in systemic lupus erythemathosus. J. Clin. Psych. 73: 993-1001. PMID:22687742

 

137. Lai, Z-W, Hanczko, R., Bonilla, E, Caza, T.N., Clair, B., Bartos, A., Miklossy, G, Jimah, J., Doherty, E, Tily, H., Francis, L, Garcia, R., Dawood, M., Yu, J., Ramos, I., Coman, I., Faraone, S.V., Phillips, P.E. and Perl, A. (2012). N-acetylcysteine reduces disease activity by blocking mTOR in T cells of lupus patients. Arthritis Rheum. 64: 2937-2946. PMID: 22549432; PMCID: PMC3411859

 

138. Alessandri, C, Barbati, C., Vacirca, D., Piscopo, P., Confaloni, A.M., Maselli, A., Colasanti, T., Conti, F., Truglia, S., Perl, A., Valesini, G, Ortona, E., Malorni, W, and Pierdominici, M. (2012) T lymphocytes from patients with Systemic Lupus Erythematosus are resistant to induction of autophagy. FASEB J. 26: 4722-4732. PMID: 22835828;  PMCID: PMC3475261

 

139. Garcia, R.J., Francis, L., Dawood, M, Lai, Z-W., Faraone, S.V., and Perl, A. (2013) Attention Deficit and Hyperactivity Disorder Scores are Elevated and Respond to NAC treatment in patients with SLE. Arthritis Rheum. 65: 1313-1318. PMID: 23400548

 

140. Singh N, Birkenbach M, Caza T, Perl A, Cohen PL. (2013) Tuberous sclerosis and fulminant lupus in a young woman.  J. Clin. Rheumatol. 19(3):134-7. doi: 10.1097/RHU.0b013e318289c033. PMID: 23519178

 

141. Gilkeson GS, Mashmoushi AK, Ruiz P, Caza TN, Perl A, and Oates JC. (2013) Endothelial Nitric Oxide Synthase Reduces Crescentic and Necrotic Glomerular Lesions, Reactive Oxygen Production, and MCP1 Production in Murine Lupus Nephritis. PLoS ONE 8(5): e64650. doi:10.1371/journal.pone.0064650 PMID: 23741359

 

142. Lai, Z-W, Borsuk, R., Shadakshari, A., Yu, J., Dawood, M., Garcia, R., Francis, F., Tily, H., Bartos, A., Faraone, S.V., Phillips, P.E. and Perl. A. (2013). mTOR activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus eryhthematosus. J. Immunol. 191: 2236-2246. doi: 10.4049/jimmunol.1301005. PMID: 23913957

 

143. Perl, A. (2013) Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat. Rev. Rheumatol. 9:674–686. PMID: 24100461

 

144. Caza, T.N., Fernandez, D.R., Talaber, G., Oaks, Z., Haas, M., Madaio, M.P., Lai, Z-W, Miklossy, G.,  Singh, R.R., Chudakov, D.M., Malorni, W., Middleton, F., Banki, K, and Perl, A. (2014) HRES-1/RAB4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. Ann. Rheum. Dis. 73:1888-1897. PMID:23897774; PMCID:PMC4047212

 

145. Oaks, Z. and Perl, A. (2014). Metabolic control of the epigenome in systemic lupus erythematosus. Autoimmunity, 47:256-264. PMCID: PMC4034124

 

146. Fali, T, Le Dantec, C, Thabet, Y., Jousse, S., Hanrotel, C., Brooks, W.H., Perl, A., and Renaudineau, Y. (2014) DNA methylation modulates HRES1/p28 expression in B cells from patients with lupus. Autoimmunity, 47:265-271. PMID: 24117194; PMCID: PMC4034120

 

147. Talaber, G., Miklossy, G., Oaks, Z, Liu, Y, Tooze, S.A., Chudakov, D.M., Banki, K. and Perl. A (2014) HRES-1/Rab4 promotes the formation of LC3+ autophagosomes and the accumulation of mitochondria during autophagy. PLoS ONE, 9(1): e84392.

 

148. Caza, T., Oaks, Z and Perl, A. (2014) Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus. Int. Rev. Immunol. 33(4):330-363.

 

149. Doherty, E, Oaks, Z. and Perl, A. (2014) Increased Mitochondrial Electron Transport Chain Activity at Complex I is Regulated by N-acetylcysteine in Lymphocytes of Patients with Systemic Lupus Erythematosus. Antioxid. Redox Signal. 21: 56-65. PMID: 24673154;

 

150. Kato, H. and Perl, A. (2014) Mechanistic Target of Rapamycin Complex 1 Expands Th17 and IL-4+ CD4-CD8- Double-Negative T Cells and Contracts Regulatory T Cells in Systemic Lupus Erythematosus. J. Immunol. 192:4134-4144; PMID: 24683191. PMCID: PMC3995867.

 

151. Oaks Z and Perl A. TALDO1 (transaldolase 1). Atlas Genet Cytogenet Oncol Haematol. Feb 2014; 18(2).

 

152. Lai, Z-W, Marchena-Mendez, I. and Perl, A. (2015) Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome. Clin. Immunol. 158:148-152. PMID: 26366134; PMCID:PMC4464983

 

153. Perl, A. (2015) mTOR Activation is a Biomarker and Central Pathway to Autoimmune Disorders, Cancer, Obesity, and Aging. Ann. NY Acad. Sci. 1346:33-44. PMID: 25907074; PMCID: PMC4480196

 

154. Liu, Y., Yu, J., Oaks, Z.,  Marchena-Mendez, I., Francis, L., Bonilla, E., Aleksiejuk, P., Patel, J, Banki, K., Landas, S.K. and Perl, A. (2015) Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus. Clin. Immunol. 160:319-327. PMID: 26366134; PMCID:PMC4583603

 

155. Perl, A., Hanczko, R., Lai, Z-W, Oaks, Z., Kelly, R., Borsuk, R., Asara, J.M., and Phillips, P.E. (2015) Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin. Metabolomics. 11:1157-1174. PMID: 26366134; PMCID: PMC4559110

 

156. Joseph, N., Zhang-James, Y., Perl, A., and Faraone, S.V. (2015) Oxidative Stress and Attention Deficit Hyperactivity Disorder: A Meta-Analysis. J. Atten. Disord. 19:915-924. PMID: 24232168; PMCID: PMC5293138

 

157. Perl, A. (2016). Mechanistic Target of Rapamycin Pathway Activation in Rheumatic Diseases. Nat. Rev. Rheumatol. 12:169-182. PMID: 24232168; PMCID: PMC5314913

 

158. Klionsky, D.H…Perl, A… (2016) Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy. Autophagy. 12: 1-122. PMID: 24232168 PMCID:PMC4835977 [Available on 2017-01-21]

 

159. Oaks, Z., Winans, T, Caza, T., Fernandez, D., Liu, Y, Landas, S.K, Banki, K. and Perl, A. (2016) Mitochondrial dysfunction in the liver and antiphospholipid antibody production precede disease onset and respond to rapamycin in lupus-prone mice. Arthritis Rheumatol. (Featured In This Issue). 68(11):2728-2739. PMID: 27332042; PMCID:PMC5083168

 

160. Perl, Al. (2016) LINEing Up to Boost Interferon Production: Activation of Endogenous Retroviral DNA in Autoimmunity. Arthritis Rheumatol. Invited Editorial. 68:2568-2570. PMID: 27338170; PMCID: PMC5083194

 

161. Buskiewicz, I.A., Montgomery, T., Yasewicz, E.C., Huber, S.A., Murphy, M.P., Hartley, R.C., Kelly, R., Crow, M.K., Perl, A, Budd, R.C. and Koenig, A. (2016) Reactive oxygen species induce virus-independent MAVS-oligomerization in systemic lupus erythematosus. Sci. Signal. Vol. 9, Issue 456, pp. ra115 DOI: 10.1126/scisignal.aaf1933. PMID: 27899525; PMCID: PMC5321043

 

162. Perl, A., Lai, Z,  Oaks, Z., Asara, A., Hanczko, R., Kelly, R., and Phillips, P. (2016).

Metabolome checkpoints of mTOR activation and clinical responsiveness in SLE. Lupus Sci. Med. (Suppl.1) A14-A15. http://dx.doi.org/10.1136/lupus-2016-000179.29

 

163. Oaks, Z, Winans, T, Huang, N, Banki, K. and Perl, A. (2016) Activation of the mechanistic target of rapamycin in SLE: Explosion of evidence in the last five years. Curr. Rheum. Rep. Dec;18(12):73. PMID.PMID: 27812954; DOI:10.1007/s11926-016-0622-8

164. Bonilla E, Shadakshari A, Perl A. (2016) Association of psoriasis and psoriatic arthritis with systemic lupus erythematosus. Rheumatol. Orthop. Med. https://oatext.com/pdf/ROM-1-105.pdf; DOI: 10.15761/ROM.1000105.

​

165. Doherty, E. and Perl, A. (2017) Measurement of Mitochondrial Mass by Flow Cytometry during Oxidative Stress. React. Oxyg. Species, 4 (10): 275-283. ISSN 2380-2367. PMID: 29806036; PMCID: PMC5964986

 

166. Perl, A. (2017) Metabolic control of immune system activation in rheumatic diseases. Arthritis Rheumatol. 69:2259-2270. PMID: 28841779 PMCID: PMC5711528 [Available on 2018-12-01]

 

167. Kato, H. and Perl, A. (2018) The IL-21-mTOR axis blocks differentiation and function of regulatory T cells of systemic lupus erythematosus patients by suppression of autophagy. Arthritis Rheumatol. 70(3):427-438. PMID: 29161463; PMCID: PMC5826851

 

168. Lai, Z, Kelly, R., Winans, T., Marchena, I., Shadakshari, A., Yu, J.,  Dawood, M., Garcia, R., Tily, H. Francis, L., Faraone, S.V .,  Phillips, P.E. and Perl, A. (2018) Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet, 391:1186-1196. PMID: 29551338;

PMCID: PMC5891154

 

169. Huang, N. and Perl, A. (2018) Metabolism as a target for modulation in autoimmune diseases. Trends Immunol. 39:562-576. PMID: 29739666;

 

170. Minchenberg SB, Chaparala G, Oaks Z, Banki K, and Perl A (2018) Systemic lupus erythematosus-myasthenia gravis overlap syndrome: Presentation and treatment depend on prior thymectomy. Clin. Immunol. 194:100-104. PMID: 30025818; PMC6089637.

 

171. Perl, A., Lai, Z, Kelly, R., Faraone, S.V., and Phillips, P.E. (2018) Sirolimus for systemic lupus erythematosus – Authors’ reply. Lancet, 392:734. PMID: 30191826;

 

172. Zhi-Wei Lai, Ryan Kelly, Thomas Winans, Ivan Marchena, Ashwini Shadakshari, Julie Yu, Maha Dawood, Ricardo Garcia, Hajra Tily, Lisa Francis, Stephen V Faraone, Paul E Phillips and Andras Perl (2018) Blockade of the mechanistic target of rapamycin elicits rapid and lasting improvement of disease activity through restraining pro-inflammatory T cell lineage specification in patients with active SLE. Lupus Sci. Med. Aug 2018, 5 (Suppl 2) A13-A14; DOI: 10.1136/lupus-2018-lsm.26

 

173. Perl, A. (2018) mTOR-Dependent Autophagy Contributes to End-Organ Resistance and Serves as Target for Treatment in Autoimmune Disease. EBioMedicine, 36:12-13; PMID: 30262258; PMC6197622; DOI: 10.1016/j.ebiom.2018.09.033

 

174. Budd, R., Perl, A., Blanco, L., Kaplan, M. J., Buskiewicz, I., Fortner, K. (2018) Redox-driven type I interferon in SLE and its treatment with MitoQ. Lupus Sci. Med. 6 (Suppl. 1) A28-A29; http://dx.doi.org/10.1136/lupus-2019-lsm.38

 

175. Liu, E. and Perl, A. (2019) Pathogenesis and treatment of autoimmune rheumatic diseases. Curr. Opin. Rheum. 31: 307-315. PMID: 30920455; PMCID: PMC6447054  [Available on 2020-05-01]

 

176. Oaks, Z., Jimah. J., Grossman, C.C., Beckford, M., Kelly, R., Banerjee, S., Niland, B., Miklossy, G., Kuloglu, Z., Kansu, A., Lee, W., Szonyi, L., Banki, K. and Perl, A., (2020) Transaldolase haploinsufficiency in subjects with acetaminophen-induced liver failure. J. Inherit. Metab. Dis. 43: 496-506. PMID: 31769880

 

177. Godavarthy, A., Kelly, R, Jimah, J., Beckford, M., Caza, T., Fernandez, D.R., Huang, N., Duarte, M., Lewis, J., Fadel, H.J., Poeschla, E.M., Banki, K. and Perl, A., (2020) Lupus-associated endogenous retroviral LTR polymorphism and epigenetic imprinting promote HRES-1/Rab4 expression and mTOR activation. JCI Insight, 5: e134010. PMID:31805010

 

178. Wyman, B. and Perl, A. (2020) Metabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseases. Curr. Opin. Rheum. 32:184-191. PMID:31895126

 

179. Greca, I., Ben Gabr, J., Perl, A., Bryant, S. and Zaccarini, D. (2020) Trauma Induced Calcium Pyrophosphate Deposition Disease of the Lumbar Spine. Case Rep. Rheumatol. https://doi.org/10.1155/2020/3218350; PMID: 32095306;

 

180. Fortner K.A., Blanco, L.P., Buskiewicz, I., Huang, N., Gibson, P.C., Cook, D.L., Yuen, P.S.T., Murphy, M.P., Perl, A, Kaplan,, M.J., Budd, R.C (2020) Targeting Mitochondrial Oxidative Stress with MitoQ Reduces NET Formation and Kidney Disease in Lupus-Prone MRL-lpr Mice. Lupus Sci. Med. PMID: 32343673; PMCID: PMC7199895; doi: 10.1136/lupus-2020-000387

​

181. Dziamski, K., Sharmeen, S., Banki, K., and Perl, A. (2020) Nine-test panel has superior sensitivity to detect antiphospholipid antibody syndrome in patients with or without SLE. Clin. Immunol. In press. PMID: 32200114; PMCID: PMC7200285 (available on 2021-05-01); DOI: 10.1016/j.clim.2020.108388

​

182. Piranavan, P., Bhamra, M. and Perl, A. (2020). Metabolic targets for treatment of autoimmune diseases. Immunometabolomics, 2020; 2(2): e200012. doi: 10.20900/immunometab20200012. PMID: 32341806; PMCID: PMC7184931

 

183. Piranavan, P. and Perl, A. (2020). Management of cardiovascular disease in patients with systemic lupus erythematosus. Expert Opin. Pharmacother. 21:1617-1628. PMID: 32511034;

 

184. Ben Gabr, J., Liu, E., Mian, S., Pillittere, J., Bonilla, E., Banki, K., Perl, A (2020) Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still’s disease: case report and review of the literature. Ann. Transl. Med. 2020 Jul;8(14):887. doi: 10.21037/atm-20-3127. PMID: 32793731; PMCID: PMC7396773.

 

185. Ben Gabr, J., Bilal, H., Mirchia, K. and Perl, A (2020) The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy. J. Investig. Med. High Impact Case Rep. 8:2324709620947266; PMID: 32757799; PMCID: PMC7412890

 

186. Ibrahim, H, Perl, A., Smith, D., Lewis, T., Kon, Z., Goldenberg, R., Yarta, K., Staniloae, C., Williams, M. (2020) Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clin. Immunol. 219:108544. PMID: 32707089;

PMCID: PMC7374140.

 

187. Pillittere, J., Mian, S., Richardson, T.E., and Perl, A. (2020) Hydroxychloroquine-Induced Toxic Myopathy Causing Diaphragmatic Weakness and Lung Collapse Requiring Prolonged Mechanical Ventilation. J. Investig. Med. High Impact Case Rep. doi: 10.1177/2324709620950113; PMID: 32787461; PMCID: PMC7427040

 

188. Kato, H. and Perl, A. (2021) Double-Edged Sword: Interleukin-2 Promotes T regulatory Cell Differentiation but Expands Interleukin-13- and Interferon-γ-producing CD8+ T cells via STAT6-GATA-3 Axis in Systemic Lupus Erythematosus. Front. Immunol. PMID: 33763079;

 

189. Klionsky, D.H…Perl, A… (2021) Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (4th edition). Autophagy. 12: 1-382. PMID: 33634751; PMCID:

 

190. Patel, A. and Perl, A. (2022). Redox control of integrin-mediated hepatic inflammation in systemic autoimmunity. Antioxid. Redox Signal. In press. PMID: 34036799

 

191. Piranavan, P. and Perl, A. (2021) Improvement of renal and non-renal SLE outcome measures on sirolimus therapy – a 21-year follow-up study of 73 patients. Clin. Immunol. 229:108781. PMID: 34144197;

 

192. Geier, C. and Perl A. (2021). Therapeutic mTOR blockade in systemic autoimmunity: implications for antiviral immunity and extension of lifespan. Autoimmun. Rev. 20:102984. PMID: 34718162; PMCID: PMC8550885

 

193. Nasr, S, Khalil, S, Poiesz, B, Banki, K, Perl, A. (2021) Pfizer–BioNTech COVID‑19 RNA vaccination induces phosphatidylserine autoantibodies, cryoglobulinemia, and digital necrosis in a patient with pre-existing autoimmunity. Clin. Immunol. Commun. 1:1-3.

 

194. Levack, R.C., Newell, K.L., Cabrera-Martinez, B., Cox, J., Perl, A., Bastacky, S.I. and Winslow, G.M. (2022) Adenosine Receptor 2a Agonists Target Mouse CD11c+Tbet+ B cells in Infection and Autoimmunity. Nat. Commun. 13:452. PMID: 35064115

 

195. Zhaomin, M, Tan, Y, Tao, J, Li, L, Wang, Hui, Yu, F., Perl, A. and Zhao, M. (2022). Renal mTORC1 Activation is Associated with Disease Activity and Prognosis in Lupus Nephritis. Rheumatology. 61:3830-3840. PMID: 35040950

 

196. El-Dokla, A., Bonilla, E. and Perl, A. (2022) Recurrent brachial plexopathy as initial presentation of systemic lupus erythematosus: a case report and review of the literature. Lupus, 31:500-504. PMID: 35259024

 

197. Caza, T., Wijewardena, C. Al-Rabadi, L. and Perl, A. (2022). Cell Type-Specific Mechanistic Target of Rapamycin-Dependent Distortion of Autophagy Pathways in Lupus Nephritis. Transl. Res. 245: 55-81. PMID: 35288362

 

198. Anuforo, A, Sandhu, M., Yu, J. and Perl, A. (2022) Appraising SARS-CoV-2 infections after full mRNA COVID-19 vaccination in patients with systemic lupus erythematosus (SLE). Clin. Immunol. Commun. 2:54-56.

 

199. Brown, J., Abboud, G., Ma, L., Choi, S-C., Kanda, N., Zeumer-Spataro, L., Lee, J., Peng, W., Cagmat, J., Faludi, T., Mohamadzadeh, M., Garrett, T., Mandik-Nayak, L., Chervonsky, A., Perl, A., and Morel, L. (2022). Microbiota-mediated skewing of tryptophan catabolism modulates CD4+ T cells in lupus-prone mice. iScience, 25:104241. PMID: 35494242; PMCID: PMC9051618

 

200. Perl, A., Agmon-Levin, N., Crispín, J.C. and Jorgensen, T.N. (2022) New Biomarkers for the Diagnosis and Treatment of Systemic Lupus Erythematosus: Connecting the dots between multi-omics and systems biology. Editorial. Front. Immunol. 13:1009038. PMID: 36311710; PMCID: PMC9599399

​

201. Nasr, S. and Perl, A. (2022) Principles behind SLE treatment with N-acetylcysteine. Immunometabolism, 4:e00010. PMID: 36312742; PMCID: PMC9605192

 

202. Oaks, Z, Patel, A, Huang, N, Choudhary, G, Winans, T, Faludi, T, Krakko, D, Duarte, M, Lewis, J, Beckford, M, Blair, S, Kelly, R, Landas, SK, Middleton, FA, Asara, JM, Chung, SK, Fernandez, DR, Banki, K, and Perl, A. (2023) Cytosolic aldose metabolism contributes to progression from cirrhosis to hepatocarcinogenesis. Nat. Metab. 5:41-60. PMID: 36658399